๐จ New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics
New in Psychopharmacology: does the experience matter for ketamine?
In 3,637 adults with depression, more intense psychedelic experiences went with greater improvement.
Observational, but a sign the experience deserves careful measurement.
https://t.co/RQsdOZ6UrA
Esketamine and Acceptance and Commitment Therapy (ACT) for Treatment-Resistant Depression: An Intervention-Development Framework and Treatment Manual https://t.co/UYxHJDFAch
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3): https://t.co/nkb3pQl1R2
Reported Safety Practices of Publicly Advertised Psychedelic Retreats https://t.co/6Ke44dMm0t
I find this study could be a useful springboard for deep discussions around safety and ethics, but NOT only from a western medical lens.
Across #PsychedelicRetreats, most organizations conducted medical history screening and recommended medication washout, but safety protocols and health professional involvement varied. https://t.co/dMAnMJ5Iix
DISCLAIMER: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions related to mental health or treatment options.
๐จ New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics
๐จ New paper alert! ๐จ Check out the latest viewpoint by our Dr. McGuire, scholar Dr. Mathai, and collaborators on minimizing risk and harm in the use of psychedelics.
Read more: https://t.co/JVznq7KczL
#Psychedelics#HarmReduction
@DocDurDur@unlimited_sci Thanks for asking! We bring this useful point up in the discussion. While we didn't look at state shame at baseline, the scores we found with psilocybin were consistent with those seen in other shame-activating experimental paradigms and higher than those seen without activation
Lots of people have been speculating about Elon Muskโs ketamine use, and so I wrote about what we do know about prolonged, heavy ketamine use in samples of recreational users. Many of these risks are well-known already in psychedelic circles. https://t.co/Wi5sBIKmKe
Today in The Drop In: Beat-era poet and artist Gerd Sternโs final chapter, new research on why guilt during a trip might actually help you heal, and monkeys tapping into plant medicine. Plus, soul retrieval and what to know before working with Datura.
https://t.co/RLPEHHOEAT
New publication in the Journal of Psychoactive Drugs led by Dr. David Mathai (@d_mathai) exploring emotions of shame and guilt that may arise during someone's psilocybin experience, and their relevance to psychological outcomes.ย https://t.co/yHVtb1bT0C
Excited to share our health policy scholar Dr. Mathai & collabs' new paper๐โจ "Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World #Psilocybin Use"๐ง ๐ฟ #Psychedelics#MentalHealth
https://t.co/16BpMetDfJ